CH 275

1 Cited Publications
カスタマーレビュー

Based on 1 publication(s) in Google Scholar

CH 275 is a peptidic somatostatin analog that acts as an agonist of SST1 (IC50 = 30.9 nM, Ki = 52 nM). The IC50 values of CH 275 for sst3, sst4, sst2, and sst5 are 345 nM, >1 μM, >10 μM, and >10 μM, respectively. CH 275 binds to SSTR1 via the IAmp9-Asp137 ion pair interaction and the hydrophobic interaction between the isopropyl group of IAmp9 and Leu107, and reduces the extracellular acidification rate. CH 275 induces weak sst1 internalization, exerts immunosuppressive effects on macrophages, and decreases macrophage viability, MCP-1 expression/secretion, and IL-8 secretion, but does not alter proMMP-9 secretion or IL-8 mRNA levels. CH 275 reduces hippocampal β-amyloid levels and alleviates plaque pathology without inducing hippocampal microglial activation. CH 275 is used in research on Alzheimer's disease, Parkinson's disease, and depression.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度 : 99.52%
  • CAS 番号: 174688-78-9
  • 分子式: C74H96N14O15S2
  • 分子量:1485.77
  • 保管条件:

    Sealed storage, away from moisture and light.

    Powder   -80°C, 2 years , -20°C, 1 year

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • プロトコル
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs

MedChemExpress(MCE)の使用を引用している文献 CH 275

More

Somatostatin Receptor アイソフォーム固有の製品をすべて表示

More
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00